Dr. Klaas Zuideveld initially joined Versameb as Chief Development Officer and took over as CEO end of 2020. Previously, he held the position of VP Pharmaceutical partnerships at Caris Life Sciences, where he was responsible for their first CDx partnership and precision medicine led clinical trials. Klaas held leadership positions of increasing responsibility at Roche in early and late-stage development leading to the approval of valganciclovir, capecitabine, bevacizumab, obinutuzumab, ocrelizumab and tocilizumab across various indications and formulations. He also worked at and consulted for Mosaic Biomedicals (acquired by Northern Biologic), T3 Pharma, Envision Sciences and Therachon (acquired by Pfizer).
December 15th, 2023